Guided Therapeutics (GTHP) Common Equity (2010 - 2025)
Guided Therapeutics (GTHP) reported Common Equity of -$132000.0 for Q4 2025, up 97.3% on a YoY basis from -$66903.2 in Q4 2024, and up 97.66% sequentially from -$5.6 million in Q3 2025.
Guided Therapeutics (GTHP) Common Equity (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Common Equity data on file, last reported at -$132000.0 in Q4 2025.
- For the quarter ending Q4 2025, Common Equity rose 97.3% year-over-year to -$132000.0; the trailing twelve-month figure through Dec 2025 stood at -$132000.0 (up 97.3% YoY), and the FY2025 full-year result was -$132000.0, up 97.3% from the prior year.
- Common Equity grew to -$132000.0 in Q4 2025, from -$5.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of -$132000.0 in Q4 2025 to a low of -$8.0 million in Q1 2021.
- A 5-year average of -$4.7 million and a median of -$4.9 million in 2024 frame the typical range for Common Equity.
- Across the five-year window, Common Equity tumbled 40.78% in 2024 and jumped 97.3% in 2025, its largest moves.
- Tracing GTHP's Common Equity over 5 years: stood at -$5.4 million in 2021, then surged by 47.05% to -$2.9 million in 2022, then sank by 32.02% to -$3.8 million in 2023, then fell by 28.46% to -$4.9 million in 2024, then jumped by 97.3% to -$132000.0 in 2025.
- Business Quant data shows GTHP's Common Equity at -$132000.0 in Q4 2025, -$5.6 million in Q3 2025, and -$5.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 52.70 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 38.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 50.07 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 25.86 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 10.33 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2.96 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 13.34 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.67 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 5.29 Bn |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -132,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -132,000.00 |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -5.47 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Dec 31, 2024 | -4.89 Mn |
| Sep 30, 2024 | -4.92 Mn |
| Jun 30, 2024 | -4.67 Mn |
| Mar 31, 2024 | -4.01 Mn |
| Dec 31, 2023 | -3.81 Mn |
| Sep 30, 2023 | -3.65 Mn |
| Jun 30, 2023 | -3.32 Mn |
| Mar 31, 2023 | -2.86 Mn |
| Dec 31, 2022 | -2.88 Mn |
| Sep 30, 2022 | -2.65 Mn |
| Jun 30, 2022 | -5.77 Mn |
| Mar 31, 2022 | -4.99 Mn |
| Dec 31, 2021 | -5.45 Mn |
| Sep 30, 2021 | -7.75 Mn |
| Jun 30, 2021 | -7.99 Mn |
| Mar 31, 2021 | -7.99 Mn |